94937-86-7

Basic information

• Product Name: 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE
• Synonyms: 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE;2-(CHLOROMETHYL)-1-PHENYL-1H-BENZIMIDAZOLE;1H-Benzimidazole, 2-(chloromethyl)-1-phenyl-;2-(ChloroMethyl)-1-phenyl-1H-benzo[d]iMidazole
• CAS NO: 94937-86-7
• Molecular Formula: C₁₄H₁₁ClN₂
• Molecular Weight: 242.7
• Mol File: 94937-86-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 408.9 °C at 760 mmHg
• Flash Point: 201.1 °C
• Appearance: /
• Density: 1.23 g/cm³
• CAS DataBase Reference: 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE(94937-86-7)
• EPA Substance Registry System: 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE(94937-86-7)

Safety Data

• Hazardous Substances Data: 94937-86-7(Hazardous Substances Data)

Usage

General Description

2-Chloromethyl-1-phenyl-1H-benzoimidazole is a chemical compound with the molecular formula C14H11ClN2. It is a benzimidazole derivative with a chloromethyl group and a phenyl group attached to the benzene ring. 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE is used in pharmaceutical research as a potential drug candidate for the treatment of various medical conditions. Its structure and properties make it a candidate for medicinal chemistry research and drug development, with potential applications in the treatment of cancer, infectious diseases, and other disorders. The compound's chemical properties and biological activities make it a promising candidate for further exploration and study in the field of medicinal chemistry and drug discovery.

InChI:InChI=1S/C14H11ClN2/c15-10-14-16-12-8-4-5-9-13(12)17(14)11-6-2-1-3-7-11/h1-9H,10H2

Upstream product

• 94937-85-6 2-chloro-N-[2-(phenylamino)phenyl]-acetamide 
• 119-75-5 2-nitro-N-phenylaniline 
• 79-04-9 chloroacetyl chloride 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 62-53-3 aniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 4857-04-9 2-chloromethyl-1H-benzimidazole 
• 98-80-6 phenylboronic acid 

Downstream Products

• 94937-93-6 2-(1H-1,2,4-triazol-1-yl)methyl-1-phenyl-1H-benzimidazole 
• 1393180-42-1 9-((1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-9H-purin-6-amine 
• 1393180-79-4 3-iodo-1-((1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1393180-98-7 4-chloro-1-(1-phenyl-1H-benzoimidazol-2-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine 
• 1393180-75-0 7-((1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

Imidazo[4,5-c]pyridine derivative and application thereof

The invention relates to a novel imidazo[4,5-c]pyridine derivative represented by a general formula I, and pharmaceutically acceptable salts, solvates or prodrugs of the novel imidazo[4,5-c]pyridine derivative, wherein the substituent R and R' are defined as in the specification. The invention also relates to an effect of the compound represented by the general formula I in inhibiting an NS5B RNA-dependent RNA polymerase (NS5B polymerase for short) which is necessary in a replication process of hepatitis c virus, also relates to an application of the compound, and pharmaceutically acceptable salts, hydrates or prodrugs of the compound in preparation of medicines for treating viral diseases, and especially relates to an application in preparation of medicines for treating and/or preventinghepatitis c.

Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B

The hepatitis C virus (HCV) NS5B polymerase is an attractive target for the development of novel and selective inhibitors of HCV replication. In this paper, the design, synthesis, and preliminary SAR studies of novel inhibitors of HCV NS5B polymerase based on the structure of tegobuvir have been described. The efforts to optimize the antiviral potency and reduce the treatment side effects with respect to genotype 1b resulted in the discovery of compound 3, which exhibited an EC50 of 1.163 nM and a CC50 >200 nM in a cell-based HCV replicon system assay. Additionally, testing for inhibition of the hERG channel showed a marked improvement over tegobuvir and the pharmacokinetic properties of compound 3 indicated that it was worthy of further investigation as a non-nucleoside inhibitor of HCV NS5B polymerase.